Eli Lilly: positive long-term data in eczema

(CercleFinance.com) - On Wednesday, Eli Lilly announced positive long-term data for Ebglyss, its treatment for moderate to severe atopic dermatitis (eczema) in adults and adolescents aged 12 and over.


In a press release, the US biopharmaceutical group reports that the monoclonal antibody achieved sustained disease control in 80% of participants in two clinical trials for up to three years.

The study was designed to follow patients over the long term, i.e. between two and three years, with patients responding favorably to treatment after 16 weeks.

These long-term data were unveiled as the annual congress of the European Academy of Dermatology and Venereal Diseases opened today in Amsterdam.

Ebglyss is a monoclonal antibody that targets IL-13, a key cytokine in atopic dermatitis, leading to skin inflammation, barrier dysfunction, itching and infection.

Copyright (c) 2024 CercleFinance.com. All rights reserved.